Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CorMedix (CRMD) Depreciation and Depletion (2016 - 2025)

Historic Depreciation and Depletion for CorMedix (CRMD) over the last 13 years, with Q3 2025 value amounting to $161917.0.

  • CorMedix's Depreciation and Depletion rose 53596.62% to $161917.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $464631.0, marking a year-over-year increase of 42162.95%. This contributed to the annual value of $153937.0 for FY2024, which is 11756.34% up from last year.
  • Per CorMedix's latest filing, its Depreciation and Depletion stood at $161917.0 for Q3 2025, which was up 53596.62% from $110993.0 recorded in Q2 2025.
  • In the past 5 years, CorMedix's Depreciation and Depletion ranged from a high of $161917.0 in Q3 2025 and a low of $11994.0 during Q1 2021
  • For the 5-year period, CorMedix's Depreciation and Depletion averaged around $43763.2, with its median value being $21554.5 (2022).
  • As far as peak fluctuations go, CorMedix's Depreciation and Depletion plummeted by 7515.25% in 2021, and later skyrocketed by 53596.62% in 2025.
  • CorMedix's Depreciation and Depletion (Quarter) stood at $20047.0 in 2021, then grew by 12.32% to $22516.0 in 2022, then fell by 25.11% to $16863.0 in 2023, then soared by 384.65% to $81727.0 in 2024, then surged by 98.12% to $161917.0 in 2025.
  • Its Depreciation and Depletion stands at $161917.0 for Q3 2025, versus $110993.0 for Q2 2025 and $109994.0 for Q1 2025.